ClinicalTrials.gg
Not yet recruitingNCT03098225ORGOUpdated Mar 15, 2023

A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy

A Phase 4 interventional study of Orbital radiotherapy and Methylprednisolone in Thyroid Associated Ophthalmopathy, sponsored by University of Pisa. Not yet recruiting. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-03-15.

Sponsored by University of Pisa · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Graves Ophthalmopathy by University of Pisa — 4 open to participants now, 4 under way, 2 of them phase 3. Graves Ophthalmopathy · University of Pisa.

Started
2024
with 1 other
Phase 4
Only one
of the 11
Registered
2nd of 11
by date

Among the 11 studies in Graves Ophthalmopathy by University of Pisa, this one is one of 2 that started in 2024, is the only one in phase 4, and was the 2nd registered.

Graves Ophthalmopathy

200 studies on the registry are indexed under Graves Ophthalmopathy; 59 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

4 of the 11 studies in Graves Ophthalmopathy by University of Pisa are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 39 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 17 (44%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Graves Ophthalmopathy by University of Pisa, or all of them as a file.
02

Study summary

Graves' orbitopathy (GO) is a disfiguring and disabling disease that profoundly impairs the quality of life of affected patients. High dose intravenous (iv) glucocorticoids (GC) (ivGC) is a well established, widely used treatment for active GO. The use of systemic glucocorticoids takes advantage from their immune suppressive and antiinflammatory actions, resulting in an overall beneficial effect ranging from \~35 to \~60% of patients in various studies. The intravenous route of administration has been shown to be superior to the oral route, both in terms of GO outcome and side effect profile. The combination of ivGC and orbital radiotherapy (OR) is used routinely in patients with moderate-severe, active GO, as a second-line treatment, as also recommended in the recent Guidelines published by the European Thyroid Association/European Group on Graves' Orbitopathy. Thus, the majority of studies have shown that OR increases the response rate to GC. Those studies were performed using oral GC, whereas it is not known whether OR potentiate also the effects of ivGC.

The present study is aimed at determining whether OR potentiate the effects of ivGC in the treatment of moderately severe and active GO, in terms of GO outcome and quality of life. A possible extension of the study can be foreseen, aimed at investigating the very long time GO outcome.

03

Conditions studied

  • Thyroid Associated Ophthalmopathy

Browse trials for

04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A diagnosis of Graves' disease based on the presence of hyperthyroidism (either untreated or treated with antithyroid drugs) associated with detectable anti-TSH receptor autoantibodies
  2. No major treatments for hyperthyroidism (thyroidectomy or radioiodine) in the last 3 months
  3. Euthyroidism on anti-thyroid medications or L'thyroxine (LT4) since at least 2 months
  4. GO symptoms lasting since no more than one year
  5. Active GO: CAS ≥ 3 out of 7 (worst eye)
  6. Moderate or moderately severe GO: at least one of the following signs (worst eye):

    • Exophthalmos ≥ 22 mm
    • Eye muscle involvement with mono-ocular ductions in any direction of gaze of less than 30° or evident dismotility
    • Diplopia according to Gorman score of grades a-c
  7. No or treatment for GO in the last 3 months
  8. No to OR: diabetes, hypertension, retinopathy of any type, glaucoma
  9. Male and female patients of age: 35-75 years
  10. Effective method of during the whole trial and at least six weeks after last intake of trial drugs (only female of reproducing age)
  11. No mental illness that prevent patients from comprehensive, written
  12. Compliant patient, regular follow-up possible

Exclusion criteria

Exclusion Criteria:

  1. Absence of Graves' hyperthyroidism (present or past)
  2. Thyroidectomy or radioiodine in the last 3 months
  3. Uncontrolled hyperthyroidism or hypothyroidism
  4. GO symptoms lasting since more than one year
  5. CAS \<3 (worst eye)
  6. Optic neuropathy
  7. to OR (diabetes, retinopathy of any kind)
  8. Pregnancy, breast-feeding women
  9. No
  10. Acute or chronic liver disease
  11. Relevant
  12. Chronic renal failure or other diseases of any relevance to prevent treatment 13) Corticosteroids or other agents within last 3 months
  13. Recent (≤1 year) history of alcoholism or drug abuse
  14. Previous orbital disease other than GO, eye injuries or surgery
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Radiotherapy

    Patients with moderately severe GO treated with Intravenous glucocorticoids associated with orbital radiotherapy

    Radiation: Orbital radiotherapy · Drug: Methylprednisolone

  • Active comparator
    No Radiotherapy

    Patients with moderately severe GO treated with Intravenous glucocorticoids alone

    Drug: Methylprednisolone

Interventions

  • RadiationOrbital radiotherapy

    A high-voltage linear accelerator will be used and a cumulative radiation dose of 20 Gy will be delivered to each eye in 10 fractionated doses over a period of 2 weeks. All patients will be treated in both eyes.

    Also known as: OR

  • Methylprednisolone pulse therapy for 12 weeks as follows: 500 mg IV once weekly for 6 weeks, then 250 mg IV once weekly for a further 6 weeks. Cumulative dose 4.5 g.

    Also known as: ivGC

06

What researchers measure

Primary outcomes

  1. Comparison of overall GO outcome determined using a composite evaluation

    A composite evaluation of GO was described previously. Improvement is defined as amelioration of two parameters in at least one eye, without deterioration of any parameters in both eyes: Deterioration is defined as worsening in two parameters in at least one eye: All other cases are defined as "no change" The parameters are: * Eyelid swelling (improvement/worsening according to EUGOGO Atlas evaluation) * Lid aperture in mm (significant variation: 2 or more mm) * Clinical activity score (CAS) (7 items: spontaneous pain, evoked pain, eyelid edema, eyelid redness, conjunctiva redness, caruncle edema, chemosis; significant change: at least 2 points) * Exophthalmos in mm (significant variation 2 or more mm) * Eye muscle involvement - diplopia score (Gorman score) (significant variation: disappearance or change in the degree, or improvement of ≥12 degrees in motility)

    Time frame: 52 weeks

Secondary outcomes

  1. Comparison of overall GO outcome determined using a composite evaluation

    A composite evaluation of GO was described previously. Improvement is defined as amelioration of two parameters in at least one eye, without deterioration of any parameters in both eyes: Deterioration is defined as worsening in two parameters in at least one eye: All other cases are defined as "no change" The parameters are: * Eyelid swelling (improvement/worsening according to EUGOGO Atlas evaluation) * Lid aperture in mm (significant variation: 2 or more mm) * Clinical activity score (CAS) (7 items: spontaneous pain, evoked pain, eyelid edema, eyelid redness, conjunctiva redness, caruncle edema, chemosis; significant change: at least 2 points) * Exophthalmos in mm (significant variation 2 or more mm) * Eye muscle involvement - diplopia score (Gorman score) (significant variation: disappearance or change in the degree, or improvement of ≥12 degrees in motility)

    Time frame: 26 weeks

  2. Comparison of a disease specific quality of life questionnaire (GO-QoL)

    Comparison of a disease specific quality of life questionnaire (GO-QoL)

    Time frame: 26 weeks

  3. GO relapse

    GO worsening in comparison with the 26 week evaluation, by a composite GO score: Worsening is defined as worsening in two parameters in at least one eye: The parameters are: * Eyelid swelling (worsening according to EUGOGO Atlas evaluation) * Lid aperture in mm (significant worsening: 2 or more mm) * Clinical activity score (CAS) (7 items: spontaneous pain, evoked pain, eyelid edema, eyelid redness, conjunctiva redness, caruncle edema, chemosis; significant worsening: at least 2 points) * Exophthalmos in mm (significant worsening: 2 or more mm) * Eye muscle involvement - diplopia score (Gorman score) (significant worsening: appearance or change in the degree, or worsening of ≥12 degrees in motility)

    Time frame: 52 weeks

  4. Comparison of a disease specific quality of life questionnaire (GO-QoL)

    Comparison of a disease specific quality of life questionnaire (GO-QoL)

    Time frame: 52 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2024; primary completion for Mar 2026, 26 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2017
First posted
Mar 31, 2017
StartEst.
Jan 1, 2024
Primary completionEst.
Mar 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Mar 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03098225
Lead sponsor
University of Pisa
Responsible party
Marinò Michele (Ricercatore (Assistant Professor), University of Pisa) — Principal investigator
First posted
Mar 31, 2017
Start date
Jan 1, 2024 (estimated)
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Mar 15, 2023

Study contacts

Michele Marinò, MD
Contact
michele.marino@med.unipi.it
+39-348-0616959
Marenza Leo, MD
Contact
marenzaleo@libero.it
+39-389-7993873

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion